Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms

Background. Platinum-based chemotherapy is the mainstay of front-line treatment of patients affected by pluri-metastatic intermediate/high grade NeuroEndocrine Neoplasms (NENs). However, there are no standard second-line treatments at disease progression. Previous clinical experiences have evidenced...

Full description

Bibliographic Details
Main Authors: Salvatore Tafuto, Claudia von Arx, Monica Capozzi, Fabiana Tatangelo, Manuela Mura, Roberta Modica, Maria Luisa Barretta, Antonella Di Sarno, Maria Lina Tornesello, Annamaria Colao, Alessandro Ottaiano
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Journal of Clinical Medicine
Subjects:
neuroendocrine neoplasms
chemotherapy
temozolomide
metronomic treatment
second-line
Online Access:https://www.mdpi.com/2077-0383/8/8/1224

Internet

https://www.mdpi.com/2077-0383/8/8/1224

Similar Items